{"id":464,"date":"2026-08-28T06:56:05","date_gmt":"2026-08-28T06:56:05","guid":{"rendered":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/"},"modified":"2026-08-28T07:31:46","modified_gmt":"2026-08-28T07:31:46","slug":"elamipretide-barth-syndrome-trial-fda-accelerated-approval","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/cn\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/","title":{"rendered":"\u827e\u62c9\u7c73\u666e\u80bd\u6cbb\u7597\u5df4\u65af\u7efc\u5408\u5f81\uff1a12 \u60a3\u8005\u8bd5\u9a8c\u548c FDA \u8bb0\u5f55\u663e\u793a\u4ec0\u4e48"},"content":{"rendered":"<p class=\"pim-standfirst wp-block-paragraph\">Elamipretide \u73b0\u5728\u62e5\u6709 FDA \u6279\u51c6\u7684\u7528\u4e8e\u72ed\u7a84\u5df4\u65af\u7efc\u5408\u5f81\u9002\u5e94\u75c7\u7684\u6210\u54c1\uff0c\u4f46\u8be5\u6279\u51c6\u53d6\u51b3\u4e8e\u4e0d\u5bfb\u5e38\u7684\u7f55\u89c1\u75be\u75c5\u6570\u636e\u96c6\u3002\u968f\u673a\u90e8\u5206\u5305\u62ec 12 \u53c2\u4e0e\u8005\uff0c\u4f46\u672a\u8fbe\u5230\u5176\u4e24\u4e2a\u4e3b\u8981\u7ec8\u70b9\u3002<\/p><div class=\"wp-block-group pim-key-takeaways\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 class=\"wp-block-heading\">\u8bb0\u5f55\u663e\u793a\u4ec0\u4e48<\/h2><ul class=\"wp-block-list\"><li>\u6240\u6709 12 \u968f\u673a\u53c2\u4e0e\u8005\u5747\u4e3a\u7537\u6027\uff0c\u5e74\u9f84\u4e3a 12 \u81f3 35 \u5c81\uff0c\u6765\u81ea\u4e00\u4e2a US \u5730\u70b9\u3002<\/li><li>\u8be5\u968f\u673a\u8bd5\u9a8c\u5728 6 \u5206\u949f\u6b65\u884c\u6216\u75b2\u52b3\u4e3b\u8981\u7ec8\u70b9\u65b9\u9762\u5e76\u672a\u663e\u793a\u51fa\u4f18\u8d8a\u6027\u3002<\/li><li>FDA \u6839\u636e\u5728\u8f83\u957f\u65f6\u95f4\u7684\u5f00\u653e\u6807\u7b7e\u968f\u8bbf\u671f\u95f4\u89c2\u5bdf\u5230\u7684\u819d\u4f38\u808c\u529b\u91cf\u800c\u52a0\u901f\u6279\u51c6\uff0c\u5e76\u9700\u8981\u8fdb\u884c\u9a8c\u8bc1\u6027\u8bd5\u9a8c\u3002<\/li><\/ul><\/div><\/div><figure class=\"wp-block-image size-full pim-article-figure\"><img loading=\"lazy\" decoding=\"async\" width=\"1536\" height=\"1024\" src=\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/mitochondrial-peptide-research-20260828.png\" alt=\"\u79d1\u5b66\u5bb6\u5ba1\u67e5\u7ebf\u7c92\u4f53\u819c\u6210\u50cf\u548c\u80fd\u91cf\u4ee3\u8c22\u6570\u636e\" class=\"wp-image-458\" srcset=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/mitochondrial-peptide-research-20260828.png 1536w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/mitochondrial-peptide-research-20260828-300x200.png 300w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/mitochondrial-peptide-research-20260828-1024x683.png 1024w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/mitochondrial-peptide-research-20260828-768x512.png 768w\" sizes=\"auto, (max-width: 1536px) 100vw, 1536px\" \/><figcaption class=\"wp-element-caption\">\u7814\u7a76\u80cc\u666f\u7684\u539f\u59cb\u793e\u8bba\u63d2\u56fe\u3002\u5b83\u4e0d\u662f\u7814\u7a76\u56fe\u3001\u60a3\u8005\u56fe\u50cf\u3001\u63d0\u4f9b\u7684\u4ea7\u54c1\u7167\u7247\u6216\u8bd5\u9a8c\u6750\u6599\u7684\u8868\u793a\u3002<\/figcaption><\/figure><h2 class=\"wp-block-heading\">\u5b66\u4e60\u8bb0\u5f55<\/h2><p class=\"wp-block-paragraph\">\u4ea4\u53c9\u7814\u7a76\u6bd4\u8f83\u4e86\u4f9d\u62c9\u7c73\u80bd\u548c\u5b89\u6170\u5242\u7684 12 \u5468\u5468\u671f\uff0c\u5e76\u901a\u8fc7\u6d17\u8131\u5206\u5f00\u3002 10 \u540d\u53c2\u4e0e\u8005\u8fdb\u5165\u4e86\u5f00\u653e\u6807\u7b7e\u6269\u5c55\uff0c\u5176\u4e2d 8 \u540d\u53c2\u4e0e\u8005\u63a5\u53d7\u4e86 168 \u5468\u7684\u8ddf\u8e2a\u3002<\/p><div class=\"wp-block-group pim-evidence-table\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><div class=\"pim-evidence-row\"><strong>\u968f\u673a\u7fa4\u4f53<\/strong><span>12 \u57fa\u56e0\u786e\u8bca\u7684\u5df4\u65af\u7efc\u5408\u5f81\u60a3\u8005<\/span><\/div><div class=\"pim-evidence-row\"><strong>\u4e3b\u8981\u7ec8\u70b9<\/strong><span>6-\u5206\u949f\u6b65\u884c\u8ddd\u79bb\u548c\u75b2\u52b3\u603b\u5206<\/span><\/div><div class=\"pim-evidence-row\"><strong>\u521d\u6b65\u7ed3\u679c<\/strong><span>\u968f\u673a\u4ea4\u53c9\u90e8\u5206\u4e2d\u4e24\u4e2a\u7aef\u70b9\u5747\u672a\u6ee1\u8db3<\/span><\/div><div class=\"pim-evidence-row\"><strong>\u6279\u51c6\u65e5\u671f<\/strong><span>2025\u5e749\u670819\u65e5<\/span><\/div><div class=\"pim-evidence-row\"><strong>\u5ba1\u6279\u7c7b\u578b<\/strong><span>\u52a0\u901f\uff1b\u9700\u8981\u9a8c\u8bc1\u6027\u8bd5\u9a8c<\/span><\/div><\/div><\/div><h2 class=\"wp-block-heading\">\u4e0a\u4e0b\u6587\u4e2d\u7684\u7ed3\u679c<\/h2><p class=\"wp-block-paragraph\">FDA \u62a5\u544a 124 \u725b\u987f\u7684\u4e2d\u4f4d\u57fa\u7ebf\u819d\u4f38\u808c\u529b\u91cf\u3002 12 \u5468\u7684\u4e2d\u4f4d\u53d8\u5316\uff08\u5b89\u6170\u5242\uff09\u4e3a -5 \u725b\u987f\uff0c\u57c3\u62c9\u7c73\u666e\u80bd\uff08elamipretide\uff09\u4e3a +4\uff1b\u5728\u5f00\u653e\u6807\u7b7e\u6269\u5c55\u671f\u95f4\u51fa\u73b0\u4e86\u66f4\u5927\u7684\u63cf\u8ff0\u6027\u53d8\u5316\uff0c\u5305\u62ec 168 \u5468\u516b\u540d\u53c2\u4e0e\u8005\u4e2d\u7684 +63 \u725b\u987f\u3002<\/p><p class=\"wp-block-paragraph\">\u5f00\u653e\u6807\u7b7e\u53d8\u66f4\u5bb9\u6613\u53d7\u5230\u65f6\u95f4\u6548\u5e94\u3001\u671f\u671b\u3001\u9009\u62e9\u6027\u5ef6\u7eed\u548c\u7f3a\u4e4f\u5e76\u53d1\u63a7\u5236\u7684\u5f71\u54cd\u3002\u56e0\u6b64\uff0cFDA \u9700\u8981\u6279\u51c6\u540e\u786e\u8ba4\u5f3a\u5ea6\u53d8\u5316\u8f6c\u5316\u4e3a\u60a3\u8005\u5229\u76ca\u3002<\/p><h2 class=\"wp-block-heading\">\u8fd9\u9879\u7814\u7a76\u65e0\u6cd5\u56de\u7b54\u4ec0\u4e48<\/h2><p class=\"wp-block-paragraph\">\u6570\u636e\u96c6\u975e\u5e38\u5c0f\uff0c\u65e0\u6cd5\u652f\u6301\u4e9a\u7ec4\u5206\u6790\u3002<\/p><p class=\"wp-block-paragraph\">\u8be5\u6279\u51c6\u9002\u7528\u4e8e Forzinity \u6cbb\u7597\u4f53\u91cd\u81f3\u5c11\u4e3a 30 \u516c\u65a4\u7684\u5df4\u65af\u7efc\u5408\u5f81\u60a3\u8005\uff0c\u4e0d\u9002\u7528\u4e8e\u901a\u7528\u201cSS-31\u201d\u6750\u6599\u6216\u5176\u4ed6\u7528\u9014\u3002<\/p>","protected":false},"excerpt":{"rendered":"<p>Elamipretide \u73b0\u5728\u62e5\u6709 FDA \u6279\u51c6\u7684\u7528\u4e8e\u72ed\u7a84\u5df4\u65af\u7efc\u5408\u5f81\u9002\u5e94\u75c7\u7684\u6210\u54c1\uff0c\u4f46\u8be5\u6279\u51c6\u53d6\u51b3\u4e8e\u4e0d\u5bfb\u5e38\u7684\u7f55\u89c1\u75be\u75c5\u6570\u636e\u96c6\u3002\u968f\u673a\u90e8\u5206\u5305\u62ec 12 \u53c2\u4e0e\u8005\uff0c\u4f46\u672a\u8fbe\u5230\u5176\u4e24\u4e2a\u4e3b\u8981\u7ec8\u70b9\u3002<\/p>","protected":false},"author":1,"featured_media":629,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"364","pim_article_type":"Published study case","pim_evidence_level":"Small randomized crossover trial plus FDA accelerated-approval record","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-28","pim_editorial_note":"Source-checked on 2026-08-28. Null findings and study limitations are retained. This is not independent peer review, medical advice, a customer case, or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"FDA Drug Trials Snapshot: Forzinity\",\"url\":\"https:\/\/www.fda.gov\/drugs\/drug-trials-snapshots\/drug-trials-snapshots-forzinity\",\"note\":\"Trial population, endpoint results and approval basis.\"},{\"title\":\"Elamipretide phase 2\/3 Barth syndrome crossover trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33077895\/\",\"note\":\"Primary published trial; PMID 33077895.\"},{\"title\":\"FDA accelerated approval announcement for Forzinity\",\"url\":\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-first-treatment-barth-syndrome\",\"note\":\"Approval scope and confirmatory requirement.\"}]","footnotes":""},"categories":[19],"tags":[],"class_list":["post-464","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-published-study-cases"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Elamipretide in Barth Syndrome: What the 12-Patient Trial and FDA Record Show - NHD<\/title>\n<meta name=\"description\" content=\"Elamipretide now has an FDA-approved finished product for a narrow Barth syndrome indication, but the approval rests on an unusual rare-disease dataset. Th\u2026\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/cn\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Elamipretide in Barth Syndrome: What the 12-Patient Trial and FDA Record Show\" \/>\n<meta property=\"og:description\" content=\"Elamipretide now has an FDA-approved finished product for a narrow Barth syndrome indication, but the approval rests on an unusual rare-disease dataset. Th\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/cn\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-28T06:56:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:31:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/elamipretide-barth-syndrome-trial-fda-accelerated-approval-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Elamipretide in Barth Syndrome: What the 12-Patient Trial and FDA Record Show\",\"datePublished\":\"2026-08-28T06:56:05+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/\"},\"wordCount\":284,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval-featured-v2.webp\",\"articleSection\":[\"Published Study Reviews\"],\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/\",\"name\":\"Elamipretide in Barth Syndrome: What the 12-Patient Trial and FDA Record Show - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval-featured-v2.webp\",\"datePublished\":\"2026-08-28T06:56:05+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"description\":\"Elamipretide now has an FDA-approved finished product for a narrow Barth syndrome indication, but the approval rests on an unusual rare-disease dataset. Th\u2026\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Elamipretide in Barth Syndrome: What the 12-Patient Trial and FDA Record Show\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/cn\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"\u827e\u62c9\u666e\u80bd\u6cbb\u7597\u5df4\u65af\u7efc\u5408\u5f81\uff1a12-\u60a3\u8005\u8bd5\u9a8c\u548c FDA \u8bb0\u5f55\u663e\u793a\u4ec0\u4e48 - NHD","description":"Elamipretide \u73b0\u5728\u62e5\u6709 FDA \u6279\u51c6\u7684\u7528\u4e8e\u72ed\u7a84\u5df4\u65af\u7efc\u5408\u5f81\u9002\u5e94\u75c7\u7684\u6210\u54c1\uff0c\u4f46\u8be5\u6279\u51c6\u53d6\u51b3\u4e8e\u4e0d\u5bfb\u5e38\u7684\u7f55\u89c1\u75be\u75c5\u6570\u636e\u96c6\u3002\u7279\u2026","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/cn\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/","og_locale":"zh_CN","og_type":"article","og_title":"Elamipretide in Barth Syndrome: What the 12-Patient Trial and FDA Record Show","og_description":"Elamipretide now has an FDA-approved finished product for a narrow Barth syndrome indication, but the approval rests on an unusual rare-disease dataset. Th\u2026","og_url":"https:\/\/nhdbio.com\/cn\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/","og_site_name":"NHD","article_published_time":"2026-08-28T06:56:05+00:00","article_modified_time":"2026-08-28T07:31:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/elamipretide-barth-syndrome-trial-fda-accelerated-approval-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"\u4f5c\u8005":"NHD Technical Team","\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4":"1 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Elamipretide in Barth Syndrome: What the 12-Patient Trial and FDA Record Show","datePublished":"2026-08-28T06:56:05+00:00","dateModified":"2026-08-28T07:31:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/"},"wordCount":284,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/elamipretide-barth-syndrome-trial-fda-accelerated-approval-featured-v2.webp","articleSection":["Published Study Reviews"],"inLanguage":"zh-Hans","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/","url":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/","name":"\u827e\u62c9\u666e\u80bd\u6cbb\u7597\u5df4\u65af\u7efc\u5408\u5f81\uff1a12-\u60a3\u8005\u8bd5\u9a8c\u548c FDA \u8bb0\u5f55\u663e\u793a\u4ec0\u4e48 - NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/elamipretide-barth-syndrome-trial-fda-accelerated-approval-featured-v2.webp","datePublished":"2026-08-28T06:56:05+00:00","dateModified":"2026-08-28T07:31:46+00:00","description":"Elamipretide \u73b0\u5728\u62e5\u6709 FDA \u6279\u51c6\u7684\u7528\u4e8e\u72ed\u7a84\u5df4\u65af\u7efc\u5408\u5f81\u9002\u5e94\u75c7\u7684\u6210\u54c1\uff0c\u4f46\u8be5\u6279\u51c6\u53d6\u51b3\u4e8e\u4e0d\u5bfb\u5e38\u7684\u7f55\u89c1\u75be\u75c5\u6570\u636e\u96c6\u3002\u7279\u2026","breadcrumb":{"@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/"]}]},{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/elamipretide-barth-syndrome-trial-fda-accelerated-approval-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/elamipretide-barth-syndrome-trial-fda-accelerated-approval-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/elamipretide-barth-syndrome-trial-fda-accelerated-approval\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Elamipretide in Barth Syndrome: What the 12-Patient Trial and FDA Record Show"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"\u591a\u80bd\u539f\u6599\u4e0e\u591a\u80bd\u5b9a\u5236\u5408\u6210","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-Hans"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"NHD\u6280\u672f\u56e2\u961f","image":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"NHD \u6280\u672f\u56e2\u961f\u7ef4\u62a4\u7814\u7a76\u7528\u9014\u76ee\u5f55\u6587\u6863\u548c\u8bc1\u636e\u6458\u8981\u3002\u7ecf\u8bc4\u5ba1\u7684\u6587\u7ae0\u94fe\u63a5\u5230\u540c\u884c\u8bc4\u5ba1\u7684\u8bba\u6587\u3001\u8bd5\u9a8c\u6ce8\u518c\u548c\u76d1\u7ba1\u8bb0\u5f55\uff0c\u4fdd\u7559\u65e0\u6548\u7ed3\u679c\u548c\u7814\u7a76\u5c40\u9650\u6027\uff0c\u5e76\u5c06\u5df2\u53d1\u8868\u7684\u5e72\u9884\u63aa\u65bd\u4e0e\u76ee\u5f55\u6750\u6599\u533a\u5206\u5f00\u6765\u3002\u7ed3\u6784\u53ef\u91c7\u7528AI\u8f85\u52a9\u7ed8\u56fe\uff1b\u6765\u6e90\u94fe\u63a5\u548c\u8bc1\u636e\u8fb9\u754c\u4ecd\u7136\u53ef\u89c1\u3002\u8fd9\u9879\u5de5\u4f5c\u4e0d\u662f\u72ec\u7acb\u7684\u540c\u884c\u8bc4\u5ba1\u6216\u533b\u7597\u5efa\u8bae\u3002","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/cn\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/cn\/wp-json\/wp\/v2\/posts\/464","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/cn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/cn\/wp-json\/wp\/v2\/comments?post=464"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/cn\/wp-json\/wp\/v2\/posts\/464\/revisions"}],"predecessor-version":[{"id":512,"href":"https:\/\/nhdbio.com\/cn\/wp-json\/wp\/v2\/posts\/464\/revisions\/512"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/cn\/wp-json\/wp\/v2\/media\/629"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/cn\/wp-json\/wp\/v2\/media?parent=464"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/cn\/wp-json\/wp\/v2\/categories?post=464"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/cn\/wp-json\/wp\/v2\/tags?post=464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}